Ferguson L R, Roberton A M, Berriman J
Cancer Research Laboratory, University of Auckland Medical School, New Zealand.
Mutat Res. 1990 Sep;245(1):41-6. doi: 10.1016/0165-7992(90)90023-d.
Mutagenicity or carcinogenicity data are not publicly available on many hair dyes or dye components commonly used within New Zealand. Representative mid- to dark-warm brown hair dyes of 12 brands supplying more than 1% of the New Zealand market were tested for direct-acting mutagenicity using the bacterial 'Ames' test. Despite recent scientific advances in the development of non-mutagenic dyes, 23 of the 40 products tested gave positive results in one or both of the tester strains used. There appeared to be differences between distributors in the proportion of their hair dyes which were mutagenic. In the case of 6 out of 10 of the above dyes which had tested positive, in vitro mutagenicity or toxicity was enhanced in the presence of verapamil, suggesting that risks from hair-dye exposure may change in the case of persons using this or similar drugs. It is recognised that there are uncertainties regarding human risks from dyes which are shown to be mutagenic in in vitro tests. However, from the above results, it seems possible to produce non-mutagenic hair dyes in this color range; and in the interests of public reassurance, it may be prudent to require that such dyes be used.
在新西兰,许多常用染发剂或染料成分的致突变性或致癌性数据并未公开。对供应超过新西兰市场1%的12个品牌的代表性中至深暖棕色染发剂进行了细菌“艾姆斯”试验,以检测其直接致突变性。尽管最近在非诱变染料的开发方面取得了科学进展,但在测试的40种产品中,有23种在使用的一种或两种测试菌株中呈阳性结果。不同经销商销售的染发剂中诱变剂所占比例似乎存在差异。在上述10种测试呈阳性的染料中,有6种在维拉帕米存在的情况下,体外致突变性或毒性增强,这表明使用这种或类似药物的人接触染发剂的风险可能会发生变化。人们认识到,对于在体外试验中显示有致突变性的染料,其对人类的风险存在不确定性。然而,从上述结果来看,似乎有可能生产出这种颜色范围内的非诱变染发剂;为了让公众放心,要求使用此类染料可能是谨慎之举。